Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regencell Bioscience ( (RGC) ) has issued an announcement.
On May 19, 2026, Regencell Bioscience announced it had entered a definitive agreement with investors for a registered direct offering of 985,222 ordinary shares at $20.30 per share, led by a $19 million commitment from a new fundamental institutional investor and additional participation from Univest Securities. The deal, conducted under an automatically effective shelf registration statement and with Univest acting as sole placement agent, is expected to raise about $20 million in gross proceeds upon closing around May 20, 2026, bolstering Regencell’s funding position amid ongoing shareholder litigation disclosed earlier in May.
More about Regencell Bioscience
Regencell Bioscience Holdings Limited is a Cayman Islands–incorporated company listed on Nasdaq under the ticker RGC and operates in the bioscience sector. The company focuses on developing and commercializing treatments within the broader life sciences market, with its principal executive offices based in Hong Kong and legal domicile in the Cayman Islands.
Average Trading Volume: 134,537
Technical Sentiment Signal: Buy
Current Market Cap: $14.13B
Learn more about RGC stock on TipRanks’ Stock Analysis page.